12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Impavido miltefosine regulatory update

Paladin said FDA accepted and granted Priority Review to an NDA for Impavido miltefosine to treat leishmaniasis. The PDUFA date is Dec. 19. Paladin said it is eligible for...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >